Loading...
•
Dec 31, 2019
Regulus Therapeutics Q4 2019 Earnings Report
Regulus Therapeutics reported financial results for Q4 2019, highlighted the FDA's removal of a partial clinical hold for the RGLS4326 Phase I study, the reinitiation of the RGLS4326 MAD study, and the closing of a $26 million financing tranche.
Key Takeaways
Regulus Therapeutics reported a net loss of $4.9 million for the fourth quarter of 2019. The company reinitiated its RGLS4326 Phase 1 study after the FDA lifted a partial clinical hold and closed a $26 million financing tranche.
FDA removed partial clinical hold for Phase I Multiple Ascending Dose Study of RGLS4326.
Regulus reinitiated the Multiple Ascending Dose Study of RGLS4326 for the treatment of ADPKD.
The company closed a $26 million second tranche of private financing.
Dosing of the second cohort in RGLS4326 Phase 1 for ADPKD was initiated in February 2020.